@Suzierizzo1 Trump's a monster...he puts real effort into lying such that his face turns purple. He's a lying sociopath:
Key tendencies include a lack of empathy or guilt, manipulative charm, impulsivity, and a chronic disregard for societal norms and the rights of others.
@Suzierizzo1@krschwartz1957 Whiny bitch, everything is rigged, everything is fake, he’s a grifting snake oil salesman who has duped millions of gullible C students, the dumbest of the dumb, the orange twat HATES being called out on lies, he’s a worthless piece of shit, apologies to shit.
@RapierDiva@Suzierizzo1@kwelkernbc It’s not his personal violence that scare anyone. It’s his awful behavior to get people to take revenge for him. He’s personally a coward! He walked out because it wasn’t going his way! If only Congress would realize that. Don’t react. Just fight him.
Clinicians described the results as “one of the most amazing things I’ve ever seen.” An experimental once-daily oral drug called daraxonrasib has produced unprecedented outcomes in advanced pancreatic cancer, reducing the risk of death by 60% compared to standard chemotherapy.
In the Phase 3 RASolute 302 trial, daraxonrasib, a RAS(ON) multi-selective inhibitor developed by Revolution Medicines, nearly doubled median overall survival from 6.6–6.7 months with chemotherapy to 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The trial, presented as a plenary session at the 2026 ASCO Annual Meeting, triggered a rare standing ovation from oncology experts.
Unlike traditional therapies, daraxonrasib effectively targets multiple KRAS variants and even wild-type RAS, offering broad applicability to the vast majority of pancreatic cancers. The drug was also far better tolerated, with only 1.2% of patients discontinuing treatment due to side effects, compared to 11.2% in the chemotherapy arm.
This represents a major advance for a disease long considered one of the most lethal in oncology. Experts are hailing daraxonrasib as a potential paradigm shift that could transform metastatic pancreatic cancer into a more manageable condition. The FDA has already granted expanded access for eligible patients.
[O’Reilly, E. M., et al. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. DOI: 10.1056/NEJMoa2605555]
@LanaMWiggins1@ChrisDJackson@alexwagner@HunterBiden Think about this. You are the reason we lost! Support the Dems you like. Don’t support those you don’t ! Primary’s are necessary to get the right candidate into the General Election! With that. Goodbye